You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
McKinsey
McKesson
Moodys
Colorcon

Last Updated: February 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,858,961


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,858,961 protect, and when does it expire?

Patent 8,858,961 protects ALPHAGAN P and is included in one NDA.

Protection for ALPHAGAN P has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-eight patent family members in nineteen countries.

Summary for Patent: 8,858,961
Title:Compositions containing alpha-2-adrenergic agonist components
Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
Inventor(s): Graham; Richard S. (Irvine, CA), Bakhit; Peter G. (Huntington Beach, CA), Olejnik; Orest (Coto De Caza, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:12/482,783
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

Drugs Protected by US Patent 8,858,961

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021770-001 Aug 19, 2005 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,858,961

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 033539   Start Trial
Australia 2001273269   Start Trial
Australia 2005220199   Start Trial
Australia 2005280259   Start Trial
Australia 2011250793   Start Trial
Australia 7326901   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Merck
Harvard Business School
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.